Feedback
Settings

Settings

Goto Application

34,158 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/12

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 3,416
1.WO/2026/101847METHODS OF INFLUENZA VACCINATION AND COMPOSITIONS FOR THE SAME
WO - 15.05.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/US2025/053858 Applicant BLUEWILLOW BIOLOGICS, INC. Inventor KALICHARRAN, Kishna
The present invention relates to compositions and methods for inducing a robust cross-strain immune protection against influenza infection in a subject. The methods comprise administering a prime-boost combination of vaccines intranasally and intramuscularly, wherein at least one of the administered vaccines is a nanoemulsion influenza vaccine.
2.WO/2026/101714UNIVERSAL T CELL TARGETED INFLUENZA VACCINE CONSTRUCT
WO - 15.05.2026
Int.Class C07K 14/11
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
11Orthomyxoviridae, e.g. influenza virus
 Appl.No PCT/US2025/052089 Applicant SAINT LOUIS UNIVERSITY Inventor HOFT, Daniel F.
The present disclosure provides compositions and methods for generation of an anti-influenza immune response. In particular, multiple T cell epitopes have been identified and further screened for those for coverage of a wide variety of different influenza strains to ensure broad coverage approaching universality. Methods for vaccinating subjects with formulations of such peptides for the treatment or prevention of influenza infection also are described.
3.WO/2026/102329METHODS AND COMPOSITIONS FOR PREDICTING RESPONSE TO ONCOLYTIC VIROTHERAPY
WO - 15.05.2026
Int.Class A61K 35/761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
 Appl.No PCT/US2025/054658 Applicant CG ONCOLOGY, INC. Inventor SHEN, Shihpei Pearl
The present invention provides methods for selecting an individual having a solid or lymphatic tumor for treatment with an oncolytic virus, comprising determining a level of one of a coxsackie adenovirus receptor (CXADR) gene and/or a level and/or a mutation of each of one or more Rb/E2F pathway genes (e.g, E2F1, E2F2, E2F3, E2F4, E2F5, RB1, RB2, RB3, CCND1, CCND2, CCND3, CCNE1, CCNE2, CDK2, CDK4, CDK6, CDKN2A (pl6/INK4A), CDKN2B, CDKN2C, CDKN2D) in a biological sample of the individual. The present invention also provides methods of treating a solid or lymphatic tumor in an individual, comprising selecting the individual for treatment with an oncolytic virus and administering an effective amount of the oncolytic virus. The treatment method may further comprise administering an effective amount of an immunomodulator. Also provided are compositions and kits for carrying out the methods.
4.WO/2026/101618ATTENUATED ONCOLYTIC VIRUS AND USES THEREOF
WO - 15.05.2026
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
 Appl.No PCT/US2025/047703 Applicant JECHO LABORATORIES, INC. Inventor ZHU, Jianwei
The present invention relates to an attenuated oncolytic virus including a recombinant polynucleotide, where the recombinant polynucleotide includes a 5'UTR, an internal ribosomal entry site (IRES), an encoding region, at least one protease cleavage site, and a 3' UTR, where the encoding region encodes an immune modulator polypeptide and uses of the attenuated oncolytic virus.
5.WO/2026/099862IMMUNOGENIC PEPTIDE ANTIBODY CONSTANT REGION MOLECULES
WO - 15.05.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/IL2025/050992 Applicant TROJAN BIO LTD. Inventor BURKOVITZ, Anat
Bispecific antibodies comprising mutations that decrease homodimerization and at least one immunogenic peptide inserted into a CHI or CL domain are provided. Proteins comprising an Fc variant of a parent Fc polypeptide wherein at least one immunogenic peptide is inserted into the parent Fc polypeptide and the insertion replaces amino acids of the parent Fc polypeptide are provided. Protein dimers and antibodies comprising the proteins of the invention are also provided as are nucleic acid molecules encoding same, pharmaceutical compositions comprising same and methods of treating cancer by administrating same. Methods of producing antibodies are also provided.
6.WO/2026/102096WTACID PEPTIDES FOR PANCREATIC CANCER AND LUNG CANCER
WO - 15.05.2026
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No PCT/US2025/054323 Applicant THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS Inventor PAHAN, Kalipada
In one aspect, the invention relates to peptides comprising a) a cell penetrating peptide (CPP) and b) a fragment of the SARS-CoV-2 spike SI peptide, derivatives thereof, and related peptides, which are useful as therapeutic agents for treating cancer; pharmaceutical compositions comprising the peptides, and methods of treating, reducing or preventing cancer, methods of increasing LDH release in a cancer cell, methods of decreasing MT I metabolism m a cancer cell, and methods of inducing apoptosis in a cancer cell using the disclosed peptides and compositions thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
7.WO/2026/099815POLYMERIC-CARBOHYDRATE CONJUGATES OR NANOPARTICLE VACCINES, METHODS AND USES THEREOF
WO - 15.05.2026
Int.Class A61K 47/61
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
61the organic macromolecular compound being a polysaccharide or a derivative thereof
 Appl.No PCT/IB2025/061410 Applicant UNIVERSIDADE DE COIMBRA Inventor ANTUNES COLAÇO, Mariana Raquel
The present disclosure relates to a polymeric-carbohydrate conjugate or nanoparticle comprising a chitosan derivative and the use of said conjugate or nanoparticle as a vaccine delivery system. Moreover, it relates to the use of said conjugate or nanoparticle in immunization or gene therapy, in particular, for the treatment of infectious diseases.
8.WO/2026/099754METHOD FOR REDUCING VIRUS SHEDDING, TISSUE COLONIZATION, AND LYMPHOID DEPLETION CAUSED BY OR ASSOCIATED WITH PCV2 INFECTION
WO - 15.05.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/IB2025/061297 Applicant BOEHRINGER INGELHEIM VETMEDICA GMBH Inventor PATTERSON, Abby, Rae
The present invention in particular relates to a method for reducing virus shedding, colonization of lymphoid tissue, and/or lymphoid depletion caused by or associated with a porcine circovirus type 2 (PCV2) infection in a pig, the method comprising administering orally to the pig an immunogenic composition comprising non-replicating PCV2 antigen. In one example, an immunogenic composition is administered via the oral route to a pig, wherein the immunogenic composition comprises a recombinantly produced and purified PCV2 ORF2 protein. This allows to simply reduce virus shedding, colonization of lymphoid tissue, and/or lymphoid depletion caused by associated with a PCV2 infection in the pigs, while simultaneously reducing the propensity for adverse reactions, eliminating the risk of injection site reactions, avoiding pain, and putting less stress on the animals.
9.WO/2026/096970EPSTEIN-BARR VIRUS ANTIGENS AND RELATED USES
WO - 07.05.2026
Int.Class A61K 39/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
 Appl.No PCT/US2025/053653 Applicant VACCINE COMPANY, INC. Inventor WEIDENBACHER, Payton, Anders-Benner
Provided herein are engineered Epstein-Barr virus (EBV) polypeptides, polynucleotides encoding the same, related vectors and vaccine compositions, and related methods of making and using said compositions. The compositions disclosed herein may be useful for vaccination against EBV.
10.WO/2026/096415EX VIVO GENERATED ANTIGEN-SPECIFIC CD4+ T CELLS WITH ENHANCED SELF-RENEWAL AND CYTOTOXIC ACTIVITY FOR IMMUNOTHERAPY OF CANCER
WO - 07.05.2026
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No PCT/US2025/052773 Applicant THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK Inventor MURANSKI, Pawel
A method for generating antigen-specific CD4+ cytotoxic T cells comprising providing a plurality of CD4+ T cells; stimulating the CD4+ T cells with at least one tumor associated-antigen (TAA) peptide and/or at least one viral peptide; and expanding the CD4+ T cells in the presence of at least one pro-inflammatory cytokine. Also provided are enriched populations and compositions comprising the generated antigen-specific CD4+ cytotoxic T cells, and methods of treating, ameliorating, or preventing cancers and disease by administering the cells to subjects.
# -